The present disclosure relates to solid state forms of Lumateperone besylate and Lumateperone tosylate:R-(−)-mandelic acid, to various intermediates, to processes for their preparation and the preparation of Lumateperone or salt thereof, to pharmaceutical compositions and their use for the treatment of central nervous system disorders.

##STR00001##

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I.

##STR00001##

or a co-crystal, solvate, salt or combination thereof.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I.

##STR00001##

or a co-crystal, solvate, salt or combination thereof.

The present invention concerns a novel process for preparing solriamfetol hydrochloride.

The present invention concerns a novel process for preparing solriamfetol hydrochloride.

The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK 1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.

The present invention relates to salt forms of the hematopoietic progenitor kinase 1 (HPK 1) inhibitors N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-5-fluorophenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide and N-(2-((2S,4S)-4-Amino-2-(hydroxymethyl)pyrrolidin-1-yl)-4-(4-cyanopyridin-3-yl)phenyl)-2-(2-fluoro-6-methoxyphenyl)pyrimidine-4-carboxamide, including methods of preparation thereof, where the compounds are useful in the treatment of HPK1 mediated diseases such as cancer.

A porous chiral material of formula [M(L).sub.1.5(A)].sup.+X.sup. wherein M is a metal ion; L is a nitrogen-containing bidentate ligand; A is the anion of mandelic acid or a related acid; and X.sup. is an anion.

A porous chiral material of formula [M(L).sub.1.5(A)].sup.+X.sup. wherein M is a metal ion; L is a nitrogen-containing bidentate ligand; A is the anion of mandelic acid or a related acid; and X.sup. is an anion.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I:

##STR00001##

or a co-crystal, solvate, salt or combination thereof.